All In Biotech

Drug Trial Radar · NCT04850118

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants With X-linked Retinitis Pigmentosa

Last checked: Nov 20, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

85

Actual

Start

Mar 14, 2024

Primary completion

Jun 30, 2026

Study completion Oct 31, 2031

Sponsor

Lead sponsor
Beacon TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR mutations.

Conditions

  • X-Linked Retinitis Pigmentosa

Interventions

  • rAAV2tYF-GRK1-hRPGRcoBiological

    Adeno-associated virus vector expressing a human RPGR gene

  • ControlDrug

    Untreated Control Group 3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of participants with a ≥15 letter increase from baseline in LLVATime frame: Day 0 - Month 12

Locations

25 sites in 4 countries. Site status is shown where the registry gives one.

  • Retina Macula Institute of Arizona

    Scottsdale, Arizona

  • Children's Hospital Los Angeles

    Los Angeles, California

  • University of Florida Health Jacksonville, Department of Ophthalmology

    Jacksonville, Florida

  • Bascom Palmer Eye Institute- University of Miami

    Miami, Florida

  • Midwest Eye Institute (Retina Partners Midwest)

    Carmel, Indiana

  • Wilmer Eye Institute at Johns Hopkins

    Baltimore, Maryland

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Duke Eye Center

    Durham, North Carolina

  • Cincinnati Eye Institute

    Cincinnati, Ohio

  • Cole Eye Institute - Cleveland Clinic

    Cleveland, Ohio

  • Casey Eye Institute, OHSU

    Portland, Oregon

  • The Center for Advanced Retinal & Ocular Therapeutics University of Pennsylvania Perelman School of Medicine

    Philadelphia, Pennsylvania

  • Mid Atlantic Retina

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Retina Consultants of Texas

    Bellaire, Texas

  • Retina Foundation of the Southwest

    Dallas, Texas

  • Baylor Eye Institute

    Houston, Texas

  • Retina Consultants of San Antonio Texas

    San Antonio, Texas

  • Sydney Eye Hospital

    Sydney, New South Wales, Australia

  • Royal Victorian Eye & Ear Hospital

    East Melbourne, Victoria, Australia

  • McGill University Health Centre - Glen Site

    Montreal, Quebec, Canada

  • Moorfields Eye Hospital

    London, United Kingdom

  • The Retina Clinic London, Institute of Ophthalmology, University College London

    London, United Kingdom

  • Oxford Eye Hospital

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.